Prevention of proliferative diabetic retinopathy and cataract in SDT rats with aminoguanidine, an anti-advanced glycation end product agent

Open Diabetes Journal

Volumn 4, Issue SPEC. ISSUE 1, 2011, Pages 108-113

  Toyoda, Fumihiko ^a,b   Kakehashi, Akihiro ^a,b   Ota, Ayumi ^a,b   Kinoshita, Nozomi ^a,b   Kambara, Chiho ^a,b   Yamagami, Hiroko ^a,b   Tamemoto, Hiroyuki ^a,b   Ueba, Hiroto ^a,b   Dobashi, Yoh ^a,b   Ishikawa, San e ^a,b   Kawakami, Masanobu ^a,b   Kanazawa, Yasunori ^a,b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Japan Diabetes Foundation   (Japan)

Author keywords

Advanced glycation end products (AGEs); Cataract; Diabetes; Diabetic retinopathy; SDT rat

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; PENTOSIDINE; PROBUCOL; PYRIDOXAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMICROSCOPY; CATARACT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFICACY; FLUORESCENCE ANALYSIS; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SPONTANEOUSLY DIABETIC TORII RAT; TREATMENT DURATION; URINE LEVEL;

EID: 80455125737     PISSN: None     EISSN: 18765246     Source Type: Journal    
DOI: 10.2174/1876524601104010108     Document Type: Article

References (26)

1. Hyman L. Epidemiology of eye disease in the elderly. Eye 1987; 1: 330-41.
2. Krumpaszky HG, Ludtke R, Mickler A, Klauss V, Selbmann HK. Blindness incidence in Germany. A population-based study from Wurttemberg-Hohenzollern. Ophthalmologica 1999; 213: 176-82.
3. Kocur I, Resnikoff S. Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol 2002; 86: 716-22.
4. Hotta N, Nakamura J, Sakakibara F, et al. Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant. Am J Physiol 1997; 273: E965-71.
5. Robison WG, Nagata M, Tillis TN, Laver N, Kinoshita JH. Aldose reductase and pericyte-endothelial cell contacts in retina and optic nerve. Invest Ophthalmol Vis Sci 1989; 30: 2293-9.
6. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46: 1473-80.
7. Lee TS, MacGregor LC, Fluharty SJ, King GL. Differential regulation of protein kinase C and (Na,K)-adenosine triphosphatase activities by elevated glucose levels in retinal capillary endothelial cells. J Clin Invest 1989; 83: 90-4.
8. Nakamura J, Kato K, Hamada Y, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999; 48: 2090-5.
9. Altomare E, Grattagliano I, Vendemaile G, Micelli-Ferrari T, Signorile A, Cardia L. Oxidative protein damage in human diabetic eye: evidence of a retinal participation. Eur J Clin Invest 1997; 27: 141-7.
10. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 1996; 98: 1667-75.
11. Hammes HP, Wellensiek B, Kloting I, Sickel E, Bretzel RG, Brownlee M. The relationship of glycaemic level to advanced glycation end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster. Diabetologia 1998; 41: 165-70.
12. Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 1997; 40: 764-9.
13. Kakehashi A, Saito Y, Mori K, et al. Characteristics of diabetic retinopathy in SDT rats. Diabetes Metab Res Rev 2006; 22: 455-61.
14. Shinohara M, Masuyama T, Shoda T, et al. A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res 2000; 1: 89-100.
15. Boehm BO, Schilling S, Rosinger S, et al. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia 2004; 47: 1376-9.
16. Hirata K, Kubo K. Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes. Endocr J 2004; 51: 537-44.
17. Hammes HP, Brownlee M, Lin J, Schleicher E, Bretzel RG. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations. Diabetologia 1999; 42: 603-7.
18. Hammes HP, Alt A, Niwa T, et al. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999; 42: 728-36.
19. Sugiyama S, Miyata T, Horie K, et al. Advanced glycation end-products in diabetic nephropathy. Nephrol Dial Transplant 1996; 11 Suppl 5: 91-4.
20. Weiss MF, Rodby RA, Justice AC, Hricik DE. Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Collaborative Study Group. Kidney Int 1998; 54: 193-202.
21. Oya T, Kumon H, Kobayashi H, et al. A novel biomarker for hyperglycemia, MRX isolated from hydrolysate of glycated proteins. Biochem Biophys Res Commun 1998; 246: 267-71.
22. Capeans Tome C, De Rojas Silva MV, Rodriguez-Garcia J, Rodriguez-Segade S, Sanchez-Salorio M. Levels of pentosidine in the vitreous of eyes with proliferative diabetic retinopathy, proliferative vitreoretinopathy and retinal detachment. Graefes Arch Clin Exp Ophthalmol 2005; 243: 1272-6.
23. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 1985; 34: 938-41.
24. Philis-Tsimikas A, Parthasarathy S, Picard S, Palinski W, Witztum JL. Aminoguanidine has both pro-oxidant and antioxidant activity toward LDL. Arterioscler Thromb Vasc Biol 1995; 15: 367-76.
25. Voziyan PA, Metz TO, Baynes JW, Hudson BG. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 2002; 277: 3397-403.
26. Stitt A, Gardiner TA, Alderson NL, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51: 2826-32.